- Home
- AKBA vs MYGN Comparison
AKBA vs MYGN Comparison
Compare AKBA & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- MYGN
- Stock Information
- Founded
- AKBA 2007
- MYGN 1991
- Country
- AKBA United States
- MYGN United States
- Employees
- AKBA N/A
- MYGN N/A
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- AKBA Health Care
- MYGN Health Care
- Exchange
- AKBA Nasdaq
- MYGN Nasdaq
- Market Cap
- AKBA 729.1M
- MYGN 642.0M
- IPO Year
- AKBA 2014
- MYGN 1995
- Fundamental
- Price
- AKBA $3.09
- MYGN $8.13
- Analyst Decision
- AKBA Strong Buy
- MYGN Hold
- Analyst Count
- AKBA 5
- MYGN 13
- Target Price
- AKBA $6.90
- MYGN $13.50
- AVG Volume (30 Days)
- AKBA 2.6M
- MYGN 957.3K
- Earning Date
- AKBA 11-06-2025
- MYGN 11-03-2025
- Dividend Yield
- AKBA N/A
- MYGN N/A
- EPS Growth
- AKBA N/A
- MYGN N/A
- EPS
- AKBA N/A
- MYGN N/A
- Revenue
- AKBA $203,733,000.00
- MYGN $832,900,000.00
- Revenue This Year
- AKBA $43.91
- MYGN $0.06
- Revenue Next Year
- AKBA $32.09
- MYGN $5.68
- P/E Ratio
- AKBA N/A
- MYGN N/A
- Revenue Growth
- AKBA 16.75
- MYGN 3.83
- 52 Week Low
- AKBA $1.52
- MYGN $3.76
- 52 Week High
- AKBA $4.08
- MYGN $22.92
- Technical
- Relative Strength Index (RSI)
- AKBA 59.78
- MYGN 57.09
- Support Level
- AKBA $2.93
- MYGN $7.68
- Resistance Level
- AKBA $3.19
- MYGN $8.50
- Average True Range (ATR)
- AKBA 0.13
- MYGN 0.37
- MACD
- AKBA 0.04
- MYGN -0.03
- Stochastic Oscillator
- AKBA 91.92
- MYGN 51.60
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.